Sinopharm (company)
Chinese state-owned enterprise
From Wikipedia, the free encyclopedia
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise. The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine (SEHK: 570, mostly via Sinopharm Group Hongkong Co., Ltd.),[5] Shanghai Shyndec Pharmaceutical (SSE: 600420, via a wholly owned research institute based in Shanghai), and Beijing Tiantan Biological Products (SSE: 600161, via China National Biotec Group).
| |||||||
.jpg) Headquarters | |||||||
| Sinopharm | |||||||
| Company type | State-owned enterprise | ||||||
| Industry | |||||||
| Founded | November 26, 1998 | ||||||
| Headquarters | 20 Zhichun Road, Haidian District, Beijing , China | ||||||
Area served | China, exported worldwide | ||||||
Key people | Liu Jingzhen (chairman & Chinese Communist Party Committee Secretary)[1][2] | ||||||
| Products | |||||||
| Revenue |  US$ 96.1 billion (2023)[3] | ||||||
| US$ 1.1 billion (2023)[3] | |||||||
| Total assets | US$ 82.8 billion (2023)[3] | ||||||
| Owner | Chinese central government (100%) | ||||||
Number of employees | 202,426 (2023)[3] | ||||||
| Subsidiaries |
| ||||||
| Chinese name | |||||||
| Simplified Chinese | 中国医药集团总公司 | ||||||
| Traditional Chinese | 中國醫藥集團總公司 | ||||||
| |||||||
| short Chinese name | |||||||
| Simplified Chinese | 国药集团 | ||||||
| Traditional Chinese | 國藥集團 | ||||||
| |||||||
| Footnotes / references in a consolidated basis; equity and profit excluded minority interests; in Chinese Accounting Standards[4] | |||||||
China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the State Council.[6]
Sinopharm was ranked 109th in the 2021 Fortune Global 500 list.[7]
History
Sinopharm was founded as China National Pharmaceutical Group Corporation (Chinese: 中国医药集团总公司) on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation (Chinese: 中国医药工业公司), China National Pharmaceutical Foreign Trade Corp. (Chinese: 中国医药对外贸易公司) and China National Medical Device (Chinese: 中国医疗器械工业公司). In 2009 it was merged with China National Biotec Group (Chinese: 中国生物技术集团公司).[citation needed]
Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.[8]
Pfizer announced the signing of a cooperation pact with Sinopharm Group in April 2023, with plans to seek approval for 12 drugs in China through 2025.[9]
COVID-19 vaccines
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[10] the Sinopharm COVID-19 vaccine,[11] or BIBP vaccine,[11][12][13] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[14] BBIBP-CorV shares similar technology with CoronaVac and BBV152, other inactivated virus vaccines for COVID-19.[15]
Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed BBIBP-CorV 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[16] In December 2020, the UAE previously announced interim results showing 86% efficacy.[17] While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and mRNA-1273 showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. BIBP-CorV could be transported and stored at normal refrigerated temperatures.[18]
BBIBP-CorV is being used in vaccination campaigns by certain countries in Asia,[19][20][21] Africa,[22][23][24] South America,[25][26][27] and Europe.[28][29][30] Sinopharm expects to produce one billion doses of BBIBP-CorV in 2021.[31] On 7 May 2021, the World Health Organization approved the vaccine for emergency use[32] and Sinopharm later signed purchase agreements for 170 million doses from COVAX.[33]
The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.[citation needed]
